About Revance
Revance news and updates
Morgan Stanley invests into Revance Therapeutics, Inc.
Morgan Stanley has invested 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC).
Jan 1, 2019 | investtribune.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX
Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic.
Jan 1, 2022 | yahoo.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX
Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic.
Jan 1, 2022 | revance.comRevance Therapeutics, Inc. launched HintMD on Sep 1st 20'.
In September 2020, Biotechnology company Revance Therapeutics has introduced a prestige aesthetics portfolio to the U.S. market, starting with its RHA Collection of hyaluronic acid dermal fillers, the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds as well as an integrated fintech platform called HintMD.
Jan 1, 2022 | datamintelligence.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX®
Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic.
Jan 1, 2022 | benzinga.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX
Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic.
Jan 1, 2022 | revance.comRevance Therapeutics, Inc. launched RHA fillers for lips on Jul 1st 22'.
Many people recognize industry names like Juvederm and Restylane, but recently Revance released premium RHA fillers for lips, under-eyes, and other areas of the face.
Jul 31, 2022 | sexualhealthusa.comRevance Therapeutics, Inc. launched RHA Dermal Filler Line on Aug 1st 20'.
For instance, in August 2020, Revance Therapeutics, Inc. launched RHA Dermal Filler Line.
Sep 5, 2022 | globenewswire.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX
Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.
Sep 11, 2022 | otcdynamics.comRevance Therapeutics, Inc. hires David as President of Revance
“David joins Revance at an exciting time, as we turn our sights towards aesthetics commercial launch, international regulatory strategy, and the advancement of our therapeutics opportunity and biosimilar to Botox® program,” said Dustin S. Sjuts, President of Revance.
Oct 17, 2022 | biospace.comRevance Therapeutics, Inc. is developing biosimilar to BOTOX
Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace.
Nov 21, 2022 | marketscreener.comRevance Therapeutics, Inc. launches DAXXIFY
Revance Therapeutics, the company behind the innovative dynamic dermal filler RHA, introduces DAXXIFY – a revolutionary, long-lasting injectable treatment for moderate-to-severe glabellar lines (frown lines) that has received FDA approval.
Dec 23, 2022 | epicentreskincare.com